Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc (NASDAQ: BCYC) is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC) for oncology indications. News about BCYC often centers on progress across its clinical pipeline, strategic collaborations, and financial updates that shape the company’s development plans.
Investors and observers following BCYC news can expect regular updates on clinical trials such as the Duravelo-1 Phase 1 study, the Duravelo-2 Phase 2/3 pivotal trial in metastatic urothelial cancer, and the Duravelo-3 and Duravelo-4 Phase 1/2 studies in Nectin-4–amplified breast cancer and non-small cell lung cancer. The company also reports on data presentations at major scientific meetings, including imaging and clinical data for BRC molecules targeting EphA2 and MT1-MMP.
Company news also covers strategic partnerships, including long-term arrangements with the UK Nuclear Decommissioning Authority, the United Kingdom National Nuclear Laboratory, and SpectronRx to support an end-to-end 212Pb radiopharmaceutical supply chain. Additional announcements highlight Board of Directors changes, formation and expansion of the Research and Innovation Advisory Board, and inducement grants to new employees under the 2024 Inducement Plan.
On this BCYC news page, readers can track press releases on quarterly financial results, regulatory interactions related to zelenectide pevedotin’s potential approval pathway, and anticipated milestones such as dose selection decisions and data disclosures. For those researching Bicycle Therapeutics stock, this news feed provides a centralized view of the company’s operational, clinical, and corporate developments over time.
Bicycle Therapeutics (NASDAQ: BCYC) announced two poster presentations at the upcoming 2025 ASCO Annual Meeting in Chicago from May 30-June 3. The first presentation will share preliminary results from the Phase 1/2 Duravelo-1 study of zelenectide pevedotin (BT8009) combined with pembrolizumab in treating previously untreated, cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. The second poster will present a phase 2/3 study (Duravelo-2) of BT8009 targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer. Both presentations are scheduled for Monday, June 2, and will be available on the company's website.
Bicycle Therapeutics (NASDAQ: BCYC) announced the granting of inducement awards to 13 new employees on May 1, 2025. The awards consist of non-qualified share options to purchase a total of 79,500 ordinary shares at an exercise price of $8.56 per share, which was the company's closing price on April 30, 2025.
The options will vest over a four-year period, with 25% vesting after one year and the remaining balance vesting monthly over the subsequent 36 months. These grants were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics presented additional human imaging data for their MT1-MMP targeting Bicycle® Radioconjugates (BRC®) at AACR 2025. The data, representing 12 patients with various solid tumors, validates MT1-MMP as a promising cancer target.
Key findings include successful imaging results from two patients:
- A 65-year-old male with advanced lung cancer showed BRC tracer uptake in primary tumor, lymph nodes, and bones
- An 84-year-old female with breast and bladder cancer demonstrated higher BRC tracer uptake in primary tumors compared to conventional imaging
The company reports positive outcomes in 12 out of 14 patients tested across various cancers. Looking ahead, Bicycle Therapeutics expects to share initial human imaging data for their second target EphA2 in late 2025, with company-sponsored radiopharmaceutical trials planned for 2026.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on April 1, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase a total of 32,400 ordinary shares.
The options were granted at an exercise price of $8.49 per share, matching Bicycle's closing trading price on March 31, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide (Bicycle®) technology, has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, at 12:45 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). The company will also make a replay of the webcast available for viewing after the event.
Bicycle Therapeutics (NASDAQ: BCYC) announced significant leadership changes to strengthen its oncology expertise. Felix J. Baker, Ph.D., will become chairman of the Board of Directors, succeeding Pierre Legault who will retire after the Annual General Meeting in June 2025. Alessandro Riva, M.D., joins the Board of Directors, while Fabrice André, M.D., Ph.D., joins the Clinical Advisory Board.
The company also announced internal promotions, with Eric Westin, M.D., elevated to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development. These appointments follow the transitions of Santiago Arroyo and Nigel Crockett to advisor roles as distinguished fellows.
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on March 3, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase 73,700 ordinary shares.
The options have an exercise price of $10.97 per share, matching Bicycle's closing price on February 28, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) reported its Q4 and full-year 2024 financial results and recent business progress. Updated Phase 1 data for zelenectide pevedotin plus pembrolizumab in metastatic urothelial cancer showed a 65% overall response rate among 20 efficacy evaluable patients. Enhanced response was observed in NECTIN4 gene-amplified breast and lung cancers, leading to FDA Fast Track designations. Several Phase 1/2 trials are expected in 2025.
The company is advancing its radiopharmaceuticals pipeline with additional MT1-MMP human imaging data expected mid-2025 and first EphA2 human imaging data planned for 2H 2025. Cash and cash equivalents were $879.5 million as of December 31, 2024, providing financial runway into 2H 2027.
R&D expenses were $49.8 million for Q4 and $173.0 million for the year, while G&A expenses were $21.6 million for Q4 and $72.2 million for the year. Net loss was $51.9 million for Q4 and $169.0 million for the year, compared to $49.1 million and $180.7 million, respectively, in 2023.
Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company specializing in bicyclic peptide technology, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat on Wednesday, February 12, at 10 a.m. ET.
The event will be accessible through a live webcast available on the Investor section of Bicycle Therapeutics' website (www.bicycletherapeutics.com). For those unable to attend live, a replay of the webcast will be archived and made available after the event.
FAQ
What is the current stock price of Bicycle Therapeutics (BCYC)?
What is the market cap of Bicycle Therapeutics (BCYC)?
